The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient
NCT ID: NCT01086111
Last Updated: 2015-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2010-02-28
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators project aims to prove that RYGBP also recovers the beta cell function (BCF) Clamp tests, the gold standard for testing IS and BCF, will be performed preoperative and early postoperatively.
Aims \& methodology:
Analysis of the short-term effect of gastric bypass and sleeve gastrectomy on insulin sensitivity and beta cell function.
Preoperative baseline insulin sensitivity and beta cell function will be assessed with euglycemic and hyperglycemic clamp tests. These results will be compared with the results of the same tests carried out 3 weeks postoperative.
To determine if the duodenal exclusion is causing this effect. The results of the clamp tests 3 weeks postoperative will be compared
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PMSF
type 2 diabetes patient receiving a protein sparing diet
No interventions assigned to this group
sleeve gastrectomy
type 2 diabetes patient receiving a gastric bypass
No interventions assigned to this group
RYGBP
type 2 diabetes patient receiving a gastric bypass
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 35 kg/m2
* Subject is capable and willing to give informed consent.
* In the surgical groups indication for surgery is approved by the local multidisciplinary obesity workgroup following the NIH guidelines of 199112.
* Patient suffers from type 2 diabetes necessitating insulin therapy.
* Subject is a non-smoker for at least 6 months prior to study start.
* Female patients of child bearing potential must use oral, injected or implanted hormonal methods of contraception from at least the commencement of their last normal period prior to the screening visit. Patients using hormonal contraception should use a barrier method in addition from screening visit until their next normal period following the end of the study.
* Female patients of non-child bearing potential defined as:
* Post-menopausal females, being amenorrhoeic for at least 1 year
* Pre-menopausal females with a documented hysterectomy or bilateral oophorectomy.
Exclusion Criteria
* BMI \< 35 kg/m2
* Patient suffers from an endocrine disease, besides diabetes and thyroid disease, such as Cushing's disease, Addison's disease, hypothalamic tumor…)
* Patient suffers from type 1 diabetes, MODY or LADA
* Patient has undergone previous surgical procedure for weight loss
* Patient is considered ASA 4 or more according to the ASA physical status classification system of the American Society of Anesthesiologists.
* Patient suffers from liver cirrhosis
* Patient uses steroids
* Patient uses cyclosporin
* Recent (\<30 days) or simultaneous participation in another clinical trial.
* Any situation that can compromise the study, including serious illness or a predictable lack of cooperation from the subject.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gasthuisberg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthias Lannoo
medical doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Leuven, gasthuisberg
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S51169
Identifier Type: -
Identifier Source: org_study_id